The stock of CytomX Therapeutics Inc (CTMX) has seen a 2.94% increase in the past week, with a -10.87% drop in the past month, and a -14.58% decrease in the past quarter. The volatility ratio for the week is 4.15%, and the volatility levels for the past 30 days are at 4.59% for CTMX. The simple moving average for the past 20 days is -4.23% for CTMX’s stock, with a -36.69% simple moving average for the past 200 days.
Is It Worth Investing in CytomX Therapeutics Inc (NASDAQ: CTMX) Right Now?
CytomX Therapeutics Inc (NASDAQ: CTMX) has a price-to-earnings ratio that is above its average at 7.36x. The stock has a 36-month beta value of 1.06. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CTMX is 76.79M, and at present, short sellers hold a 7.90% of that float. On November 07, 2024, the average trading volume of CTMX was 699.41K shares.
CTMX) stock’s latest price update
The stock of CytomX Therapeutics Inc (NASDAQ: CTMX) has increased by 2.50 when compared to last closing price of 1.00.Despite this, the company has seen a gain of 2.94% in its stock price over the last five trading days. globenewswire.com reported 2024-09-09 that SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors.
Analysts’ Opinion of CTMX
Many brokerage firms have already submitted their reports for CTMX stocks, with Piper Sandler repeating the rating for CTMX by listing it as a “Overweight.” The predicted price for CTMX in the upcoming period, according to Piper Sandler is $3.50 based on the research report published on May 28, 2024 of the current year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see CTMX reach a price target of $8. The rating they have provided for CTMX stocks is “Outperform” according to the report published on May 09th, 2024.
Jefferies gave a rating of “Buy” to CTMX, setting the target price at $8 in the report published on May 06th of the current year.
CTMX Trading at -10.17% from the 50-Day Moving Average
After a stumble in the market that brought CTMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.48% of loss for the given period.
Volatility was left at 4.59%, however, over the last 30 days, the volatility rate increased by 4.15%, as shares sank -8.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.07% lower at present.
During the last 5 trading sessions, CTMX rose by +2.44%, which changed the moving average for the period of 200-days by -33.33% in comparison to the 20-day moving average, which settled at $1.0698. In addition, CytomX Therapeutics Inc saw -33.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTMX starting from Landau Jeffrey B, who sale 4,181 shares at the price of $1.23 back on Aug 20 ’24. After this action, Landau Jeffrey B now owns 119,056 shares of CytomX Therapeutics Inc, valued at $5,139 using the latest closing price.
BELVIN MARCIA, the SVP, Chief Scientific Officer of CytomX Therapeutics Inc, sale 4,181 shares at $1.23 during a trade that took place back on Aug 20 ’24, which means that BELVIN MARCIA is holding 175,648 shares at $5,139 based on the most recent closing price.
Stock Fundamentals for CTMX
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.98 for the gross margin
The net margin for CytomX Therapeutics Inc stands at 0.09. The total capital return value is set at 0.35.
Based on CytomX Therapeutics Inc (CTMX), the company’s capital structure generated -0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -7.3. The debt to equity ratio resting at -0.38. The interest coverage ratio of the stock is 2.44.
Currently, EBITDA for the company is -4.31 million with net debt to EBITDA at -4.42. When we switch over and look at the enterprise to sales, we see a ratio of 0.4. The receivables turnover for the company is 43.09for trailing twelve months and the total asset turnover is 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.00.
Conclusion
To sum up, CytomX Therapeutics Inc (CTMX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
